A combinatorial approach of the PD-L1 inhibitor, atezolizumab, and the small molecule MEK-inhibitor, cobimetinib, was studied in a randomized phase-2 study of 77 patients with PD-L1 positive CCA. This evidence concerns the gene MAP2K7 and cholangiocarcinoma.